<p>1. Translating animal models of obesity and diabetes to the clinic<br>2. Biomarker-guided drug development for better defined early patient studies and clinical trial efficiency<br>3. Modeling and simulation in the translational pharmacology of cns drugs<br>4. Functional measurements of central nervous system drug effects in early human drug development<br>5. Experimental medicine approaches in cns drug development<br>6. New approaches in translational medicine for phase i clinical trials of cns drugs<br>7. Translational approaches for antidepressant drug development<br>8. Biomarker opportunities to enrich clinical trial populations for drug development in schizophrenia and depression<br>9. Applications of neuroimaging biomarkers in cns drug development<br>10. Pet occupancy and competition in translational medicine and cns drug development<br>11. Stable isotope labeling kinetics in cns translational medicine: introduction to silk technology<br>12. Applications of neurophysiological biomarkers in cns drug development: focus on psychoses<br>13. Heart rate variability as a translational biomarker for emotional and cognitive deficits<br>14. Drug discovery in psychiatry: time for human genome-guided solutions<br>15. Use of cognition to guide decisions about the safety and efficacy of drugs in early-phase clinical trials<br>16. Digital biomarkers in clinical drug development<br>17. Lessons learned from public private partnerships and consortia: the adni paradigm<br>18. Regulatory perspectives on the use of biomarkers and personalized medicine in cns drug development: the fda viewpoint<br>19. Regulatory considerations for the use of biomarkers and personalized medicine in cns drug development: a european perspective<br>20. Regulatory science objectives and biomarker qualification through public-private partnerships are critical to delivering innovative treatments for cns diseases<br>21. The assessment of cognition in translational medicine: a contrast between the approaches used in alzheimer’s disease and major depressive disorder<br>22. Translational medicine strategies in drug development for neurodevelopmental disorders<br>23. Translational medicine strategies in drug development for mood disorders<br>24. Translational medicine strategies in alzheimer’s disease drug development<br>25. Experimental medicine models in generalized anxiety disorder and social anxiety disorder<br>26. Translational medicine strategies in ptsd drug development<br>27. Unmet medical needs in the treatment of depression and the clinical development of a differentiated antidepressant: a translational line of evidence<br>28. Translating neurobiology into practice in tobacco, alcohol, drug, and behavioral addictions<br>29. Translational medicine strategies for drug development for impulsive aggression<br>30. Hypothesizing major depression as a subset of reward deficiency syndrome (rds) linked to polymorphic reward genes: considerations for translational medicine approaches for future drug development<br>31. Traveling through the storm: leveraging virtual patient monitoring and artificial intelligence to observe, predict, and affect patient behavior in cns drug development</p>
